Abstract
Diabetic Peripheral Neuropathic Pain (DPNP) is a leading complication of diabetes that can have marked impacts on quality of life, may lead to increased depressive symptoms, and can be difficult to treat due to medication side effects. As a result, there has been growing interest in exploring adjunctive treatment options for chronic neuropathic pain, including medical cannabinoids. While the pathogenesis of DPNP is not fully understood, there is evidence that persistent hyperglycemia contributes to a number of processes leading to vascular damage, increased oxidative stress, and release of free radicals and pro-inflammatory molecules4,5—all of which may lead to DPNP symptoms, including pain.